<DOC>
	<DOCNO>NCT00818779</DOCNO>
	<brief_summary>The investigator aim assess new blood pressure medication , aliskiren , reduce various biomarkers heart disease find blood patient history heart disease type 2 diabetes . The primary hypothesis aliskiren reduce biomarkers compare calcium channel blocker .</brief_summary>
	<brief_title>Direct Renin Inhibition Effects Atherosclerotic Biomarkers</brief_title>
	<detailed_description>Agents attenuate renin angiotensin system ( RAS ) , i.e . angiotensin convert enzyme inhibitor ( ACE-Is ) angiotensin receptor blocker ( ARB ) , show therapeutic benefit variety cardiovascular disorder . ACE-Is consider standard care secondary prevention CAD AHA/ACC . Based HOPE study , beneficial effect ACE-Is patient high risk cardiovascular outcome may beyond mere blood pressure control . In addition effect blood pressure , aldosterone , sodium water absorption , blockade RAS ACE-Is ARBs alter key biomarkers vascular inflammation , vascular endothelial function , fibrinolytic balance . These surrogate biomarkers think play role progression atherosclerosis . Biomarkers vascular inflammation include vascular intracellular cell adhesion molecule ( VCAM ICAM respectively ) c-reactive protein ( CRP ) . Markers endothelial function include endothelin-1 ( ET-1 ) vasodilator nitric oxide ( NO ) . Plasminogen activator inhibitor-1 ( PAI-1 ) prothrombotic marker associate plaque proliferation atherosclerosis progression . ACE-Is block conversion angiotensin 1 ( Ang 1 ) angiotensin 2 ( Ang 2 ) . `` ACE escape '' may attenuate influence ACE-Is despite proven benefit clinical trial . Aliskiren first direct renin inhibitor approve FDA treatment hypertension . It specific potent inhibitor human renin . As may offer advantage ACE-I ARB therapy block rate limit step RAS . It show compensatory increase RAS activity note ARBs non-ACE production Ang 2 see ACE-Is . Aliskiren appear additive blood pressure lower effect add ACE-I ARB therapy . A commonly prescribed antihypertensive , dihydropyridine calcium channel blocker amlodipine , synergistic effect lower BP use ACE-I . It show mixed effect atherosclerotic biomarkers variety subject . Type 2 diabetes affect many atherosclerotic marker describe confound variable research involve biomarkers . With addition new therapeutic agent affect RAS , different pharmacodynamic effect RAS compare ACE-I ARB therapy , Ang 2 level fully block ACE-I therapy , critical good understand new class direct renin inhibitor may influence atherosclerotic biomarkers patient variety cardiovascular disorder . The objective application determine whether direct renin inhibitor , aliskiren , affect atherosclerotic biomarkers patient stable coronary artery disease diabetes currently receive standard ACE-I therapy aliskiren favorable effect marker compare calcium antagonist amlodipine . Large clinical trial proven benefit RAS blockade reduce cardiovascular morbidity mortality . The significance research information need well understand antihypertensive agent , particularly block RAS , reduce cardiovascular disease beyond blood pressure reduction alone . Research elucidate agent may reduce atherosclerosis important help well target drug therapy condition lead cause death country .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Diagnosis type 2 diabetes Diagnosis coronary artery disease Currently receive therapy ACEInhibitor Angiotensin Receptor Blocker Currently receive antiplatelet therapy statin therapy Baseline blood pressure &gt; 100/75 mm Hg BMI 2535 kg/m2 Concurrent calcium channel blocker therapy Documented peripheral edema Hyperkalemia Serum creatinine &gt; 2.0 Diagnosed proteinuria Diagnosed liver dysfunction serious rheumatological disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>diabetes</keyword>
	<keyword>heart disease</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>